Skip to main content

NRx Pharmaceuticals, Inc. (NRXP)

NASDAQ: NRXP · Delayed Price · USD
9.98
-0.03 (-0.30%)
After-hours:Sep 23, 2021 7:28 PM EDT
10.01
-0.13 (-1.28%)
At close: Sep 23, 4:00 PM
Market Cap537.73M
Revenue (ttm)n/a
Net Income (ttm)-349.22M
Shares Out41.73M
EPS (ttm)-26.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume833,532
Open10.14
Previous Close10.14
Day's Range9.81 - 10.21
52-Week Range8.39 - 76.99
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About NRXP

NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depres...

IndustryBiotechnology
Founded2015
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolNRXP
Full Company Profile

Financial Performance

Financial Statements

News

IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals

IQVIA (IQV) and NRx are set to work closely to support activities essential for emergency use authorization of ZYESAMI.

1 week ago - Zacks Investment Research

Why Are NRx Pharma Shares Moving Higher On Tuesday Premarket?

Iqvia Holdings Inc (NYSE: IQV) has collaborated with NRx Pharmaceuticals Inc (NASDAQ: NRXP) to provide pharmacovigilance services and medical information in preparation for potential regulatory actions....

1 week ago - Benzinga

IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, toda...

Other symbols:IQV
1 week ago - Business Wire

NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

RADNOR, Pa., Sept. 8, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C.

2 weeks ago - PRNewsWire

NRx Pharma Stock Is Moving Higher On COVID-19 Candidate Data

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced an additional finding from its Phase 2b/3 trial investigating Zyesami (aviptadil) for critically ill COVID-19 patients with acute respiratory failure...

3 weeks ago - Benzinga

NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinicall...

RADNOR, Pa., Aug. 30, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced an additional finding in its phase 2b/3 clinical trial investigating ZYESAMI™ (aviptadil) for the treatment ...

3 weeks ago - PRNewsWire

NRx Pharma, Cardinal Health Ink Zyesami Distribution Pact

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has signed an agreement with Cardinal Health Inc (NYSE: CAH) to provide third-party logistics and distribution of Zyesami upon the potential FDA Emergency Use Auth...

Other symbols:CAH
4 weeks ago - Benzinga

NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies

RADNOR, Pa., Aug. 26, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of Z...

4 weeks ago - PRNewsWire

NRx Pharmaceuticals Announces Closing of $30 Million Private Placement

RADNOR, Pa., Aug. 24, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of co...

4 weeks ago - PRNewsWire

Why NRx Pharmaceuticals Stock Vaulted Higher Today

Investors cheered reports in Israel that COVID-19 vaccine candidate BriLife appears to provide protection for at least six months after a second dose.

1 month ago - The Motley Fool

Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary

RADNOR, Pa., Aug. 23, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports1 in the Israeli media that participants in the BriLif...

1 month ago - PRNewsWire

NRx Pharma Stock Under Pressure On Equity Raise Of $30M

NRx Pharmaceuticals Inc (NASDAQ: NRXP) stock shed yesterday's gains after announcing a private placement of 2.72 million shares. The purchase price for one share of common stock and one investment optio...

1 month ago - Benzinga

Why NRx Pharmaceuticals Stock Is Sinking Today

The company announced a price placement for more than 2.7 million new shares and stock options.

1 month ago - The Motley Fool

NRx Pharmaceuticals Announces $30 Million Private Placement

RADNOR, Pa., Aug. 19, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with invest...

1 month ago - PRNewsWire

Why NRx Pharmaceuticals Stock Jumped 11.8% Today

The company provided a positive update from a clinical study evaluating its COVID-19 therapy Zyesami.

1 month ago - The Motley Fool

Why NRx Pharma Stock Is Trading Higher In Mid Day Session Wednesday?

Rx Pharmaceuticals Inc (NASDAQ: NRXP) shares are up around 25% during mid-day session on mild volume, in reaction to safety update on Zyesami (aviptadil) ACTIV-3 Critical Care Phase 3 study in COVID-19 ...

1 month ago - Benzinga

NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care ...

RADNOR, Pa., Aug. 18, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tes...

1 month ago - PRNewsWire

NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter end...

1 month ago - PRNewsWire

NRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021

--Company to Host Conference Call August 17, 2021 at 8:30AM ET-- RADNOR, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical compa...

1 month ago - GlobeNewsWire

NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021

RADNOR, Pa., Aug. 10, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced that the NRx Team, together with Prof Jonathan Jav...

1 month ago - PRNewsWire

NRx Pharma Starts Mid-Stage COVID-19 Vaccine Trial In Nation of Georgia

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has initiated a phase 2b dose-confirmatory trial of the BriLife vaccine against COVID-19 in the Nation of Georgia.  The vaccine is developed by the Israel Institut...

1 month ago - Benzinga

NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia

RADNOR, Pa., Aug. 9, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial...

1 month ago - PRNewsWire

MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The T...

WESTLAKE VILLAGE, Calif., Aug. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) has partnered with NRx Pharmaceuticals (Nasdaq: NRXP) (NRx) to evaluate the feasibility of formulating a dry po...

Other symbols:MNKD
1 month ago - PRNewsWire

NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Condit...

RADNOR, Pa., Aug. 4, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI™ (a...

Other symbols:MNKD
1 month ago - PRNewsWire

NRx Pharma Stock Gains On Emergency Use Nod For Zyesami To Treat COVID-19 Patients In Nation Of Georgia

The Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for NRx Pharmaceuticals Inc's (NASDAQ: NRXP) intravenous Zyesami (aviptadil) to treat critical CO...

1 month ago - Benzinga